Telehealth follow up consultations after a surgical operation have become preferred compared to in-person visits, according to 2 recent studies.
Telehealth follow up consultations after a surgical operation have become preferred compared to in-person visits, according to 2 recent studies.
A prospective pilot study from Vanderbilt University Medical Center, published in the Journal of the American College of Surgeons, tracked 50 patients who completed both online and in-person visits after certain operations: elective laparoscopic cholecystectomy, laparoscopic ventral hernia repair, umbilical hernia repair, or inguinal hernia repair.
The researchers found that 76% of patients said online visits were acceptable as the only form of follow-up care, and surgeons participating said that for 68% of patients, online visits were just as effective as in-person visits.
Despite optimism from patients and surgeons, the researchers warned about potential detriments when using telehealth as a follow up after an operation, such as liability concerns, provider work burden, and modified patient-provider relationships.
“Some operations simply require an in-person assessment. We think the key is designing our tools for online care and developing appropriate standards for adequate online assessment so that providers can determine when online care is adequate and when in-person care may be needed,” lead study author Kristy Kummerow Broman, MD, MPH, said in a statement.
Meanwhile, in a research letter published in JAMA Surgery, on which Dr Kummerow Broman was a co-author, a study of telehealth postoperative visits among veterans determined that telehealth can adequately identify whether veterans require in-person assessment or further care.
A total of 23 veterans completed 3 types of postoperative visits: telephone, in-person, and video. According to the researchers, there was no instances in which providers failed to detect a wound or postoperative complication via phone or video. Furthermore, a majority of veterans preferred the telehealth option: 39% preferred the telephone and 30% preferred video. Those who preferred the telehealth visit had to travel farther than those who preferred in-person visits.
“This has implications for waitlist management, costs, and access to care for veterans and the Veterans Affairs health care system,” the authors concluded.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More